MX2021009789A - Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada. - Google Patents

Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada.

Info

Publication number
MX2021009789A
MX2021009789A MX2021009789A MX2021009789A MX2021009789A MX 2021009789 A MX2021009789 A MX 2021009789A MX 2021009789 A MX2021009789 A MX 2021009789A MX 2021009789 A MX2021009789 A MX 2021009789A MX 2021009789 A MX2021009789 A MX 2021009789A
Authority
MX
Mexico
Prior art keywords
myasthenia gravis
treatment
antibodies
dosage
administration
Prior art date
Application number
MX2021009789A
Other languages
English (en)
Spanish (es)
Inventor
Wei- Jian PAN
Kenji Fujita
Nishi Rampal
Kaushik Patra
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2021009789A publication Critical patent/MX2021009789A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021009789A 2019-02-14 2020-02-13 Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada. MX2021009789A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962805350P 2019-02-14 2019-02-14
US201962814935P 2019-03-07 2019-03-07
PCT/US2020/018113 WO2020168079A1 (en) 2019-02-14 2020-02-13 Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis

Publications (1)

Publication Number Publication Date
MX2021009789A true MX2021009789A (es) 2021-11-17

Family

ID=69954108

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009789A MX2021009789A (es) 2019-02-14 2020-02-13 Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada.

Country Status (9)

Country Link
US (2) US20200331993A1 (enExample)
EP (1) EP3924380A1 (enExample)
JP (2) JP2022520107A (enExample)
KR (2) KR20260046520A (enExample)
CN (2) CN113614106A (enExample)
AU (1) AU2020223298A1 (enExample)
CA (1) CA3130300A1 (enExample)
MX (1) MX2021009789A (enExample)
WO (1) WO2020168079A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
DE102021120603A1 (de) * 2020-08-24 2022-02-24 Nvidia Corporation Techniken des maschinellen lernens zur sauerstofftherapievorhersage unter verwendung von medizinischen bildgebungsdaten und klinischen metadaten
EP4281472A1 (en) * 2021-01-22 2023-11-29 Alexion Pharmaceuticals, Inc. Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
US20250154232A1 (en) * 2021-07-14 2025-05-15 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CA3024618A1 (en) * 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CN118512588A (zh) * 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用

Also Published As

Publication number Publication date
KR20210126045A (ko) 2021-10-19
KR20260046520A (ko) 2026-04-07
US20200331993A1 (en) 2020-10-22
JP2025092553A (ja) 2025-06-19
CN113614106A (zh) 2021-11-05
CA3130300A1 (en) 2020-08-20
JP2022520107A (ja) 2022-03-28
AU2020223298A1 (en) 2021-09-02
EP3924380A1 (en) 2021-12-22
WO2020168079A1 (en) 2020-08-20
CN119326881A (zh) 2025-01-21
US20250243264A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
CO2020004831A2 (es) Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa
MX2021009789A (es) Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada.
MX2021008919A (es) Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua).
CO2020014773A2 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
MX2024006462A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
CL2023003607A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
CO2020004838A2 (es) Dosis y administración de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxística nocturna (hpn) y el síndrome hemolítico urémico atípico (shua)
EA201790339A1 (ru) Комбинированные препараты с антителами к cd40
EA201991876A1 (ru) Антитела против фактора d и их применения
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
MX2021004351A (es) Metodo para el tratamiento de miastenia grave.
MA53765B2 (fr) Tubulysines et conjugués tubulysines-protéines
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
EA201890340A1 (ru) Моноклональное антитело-ингибитор фактора xiia
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
EA202191470A1 (ru) Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
BR112022011280A2 (pt) Anticorpo anti-cd5 para o tratamento da disfunção do espectro da neuromielite óptica
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.
EA202192249A1 (ru) Доза и введение антител к c5 для лечения генерализованной миастении гравис